Kanjinti

Trastuzumab, the active ingredient in Kanjinti, is a monoclonal antibody presented as an intravenous solution for intravenous use. It targets HER2‑positive tumors and is employed in the treatment of certain breast and gastric cancers in adult patients.

GNH USA supplies Kanjinti as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics to ensure product integrity across global markets. All shipments comply with EU pharmacovigilance and import regulations, making Kanjinti readily available for clinical use.

Kanjinti (trastuzumab) is used in HER2‑targeted therapy for cancers that overexpress the HER2 receptor. - HER2‑positive breast cancer: improves disease‑free and overall survival in early and metastatic settings. - HER2‑positive gastric cancer: enhances response rates and prolongs survival in advanced disease. - Metastatic HER2‑positive breast cancer: provides clinical benefit when combined with chemotherapy.

Trastuzumab may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Infusion‑related reactions (fever, chills, flushing) - Nausea - Fatigue - Diarrhea

Serious or Rare Side Effects: - Cardiac toxicity (decreased left ventricular ejection fraction) - Severe infusion reactions (anaphylaxis, bronchospasm) - Pulmonary toxicity (interstitial pneumonitis) - Hematologic abnormalities (thrombocytopenia, neutropenia)

When using Kanjinti, clinicians should observe several safety measures to minimize risks. - Cardiac monitoring: assess baseline and periodic left ventricular function. - Infusion precautions: administer under medical supervision with pre‑medication as needed. - Pregnancy and lactation: avoid use; safety not established. - Hypersensitivity: discontinue if severe allergic reaction occurs. - Concomitant anthracyclines: avoid concurrent use due to increased cardiotoxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Trastuzumab can interact with other medicines, influencing safety or efficacy.

Major Interactions (Avoid): - Anthracyclines (e.g., doxorubicin): combined use heightens risk of cardiac damage. - Live vaccines: immunosuppression may increase infection risk. - Other HER2‑targeted agents (e.g., pertuzumab) used simultaneously: overlapping toxicities.

Moderate Interactions (Monitor Closely): - Cardiotoxic drugs (e.g., cyclophosphamide): monitor cardiac function. - Hormonal therapies (e.g., tamoxifen): observe for additive side effects. - Anticoagulants: watch for bleeding if thrombocytopenia occurs.